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T-cells infiltrating neoplastic lesions are believed to mediate
tumour-specific immune responses (Rosenberg, 1996). However,
in vitro studies of freshly isolated tumour-infiltrating lymphocytes
(TIL) have shown that such T-cells often have impaired effector
functions (Whiteside et al, 1992). Immunosuppressive conditions
within the tumour environment, possibly dictated by cytokines
such as interleukin (IL)-10 and transforming growth facter beta
(TGF-b), may account for the low activation state of tumour-infil-
trating T-cells (Kiessling et al, 1996). Alternatively, alterations to
the signal transduction machinery within the T-cells may hamper
effective activation upon recognition of (tumour-associated) anti-
gens (Kiessling et al, 1996; Levey and Srivastava, 1996).
The loss of signal transducing zeta (z) chains from the T-cell
receptor (TCR) complex of peripheral T-cells was first reported in
tumour-bearing mice (Mizoguchi et al, 1992). z Chains are usually
present in T-cells as disulphide-linked, transmembrane homod-
imers that are associated with the CD3 complex (Robey and
Allison, 1995). Previous studies revealed a reduced expression of
CD3-z chain on peripherally circulating and/or tumour-infiltrating
lymphocytes from patients with colorectal cancer (Nakagomi et al,
1993; Matsuda et al, 1995; Mulder et al, 1997), renal cell carci-
noma (Finke et al, 1993; Kono et al, 1996b), ovarian cancer (Lai
et al, 1996), and melanoma (Zea et al, 1995). Moreover, inverse
correlations between the level of CD3-z chain expression, the
stage of colorectal carcinoma (Matsuda et al, 1995; Mulder et al,
1997), and the survival rate among melanoma patients (Zea et al,
1995), strongly suggest that such a reduction in CD3 z chain
expression indeed leads to an impaired tumour-specific immunity.
In line with this, the absence of z chains has been correlated to a
reduced proliferative and cytokine production capacity of mature
T-cells (Mizoguchi et al, 1992; Finke et al, 1993; Zea et al, 1995;
Tartour et al, 1995; Lai et al, 1996).
In patients with colorectal carcinoma the level of CD3-z expres-
sion on mucosal T-cells was found to be inversely related to their
distance from the tumour site (Matsuda et al, 1995). In addition,
both in renal cell and in colorectal cancer patients, a higher expres-
sion of CD3-z was found on peripheral T-cells than on tumour-
infiltrating T-cells (Finke et al, 1993; Nakagomi et al, 1993;
Matsuda et al, 1995). These results indicate that the observed loss
of z chain expression may be caused by tumour-derived factors.
We have previously studied local and systemic immune parame-
ters in patients with malignant and premalignant lesions of the
cervix uteri (Cromme et al, 1993, 1995; de Gruijl et al, 1996a,
1996b). The development of cervical cancer is strongly associated
with the presence of oncogenic human papillomavirus (HPV)
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regulation of z chain expression on T-cells in cervical carcinoma. Paraffin-embedded or snap-frozen sections from 24 different cervical cancer
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Antigen retrieval by sodium citrate/microwave treatment was essential for z staining of paraffin sections. The amount of z positive cells was
quantitated and related to the number of CD3-e+ cells in corresponding tumour areas. Of the 24 cervical cancer specimens studied, z chain
dimer expression was reduced in seven cases and strongly reduced in the other 17 samples. In tonsil control sections, CD3-e and CD3-z were
always co-expressed in almost equal numbers. Also, both tumour-negative and -positive lymph nodes showed z chain expression which
equalled that of CD3-e expression. These data indicate that a decreased expression of signal-transducing z molecules on tumour-infiltrating
T-cells is frequent in cervical cancer. The apparently unimpaired z chain expression within draining lymph nodes suggests that local tumour-
derived factors at the primary site are instrumental in z chain down-regulation.
Keywords: cervical carcinoma; cervical dysplasia; T-lymphocytes; z chain
1127
British Journal of Cancer (1999) 79(7/8), 1127–1132
© 1999 Cancer Research Campaign
Article no. bjoc.1998.0179
Received 25 March 1998
Revised 30 July 1998
Accepted 3 August 1998
Correspondence to: RJ Scheper, Department of Pathology, Free University
Hospital, PO Box 7057, 1007 MB Amsterdam, The Netherlandstypes (IARC, 1995). The failure of the host immune system to
raise effective immune responses to HPV-derived antigens is
believed to play an important role in cervical carcinogenesis. This
is exemplified by increased prevalences of HPV-induced cervical
lesions in patients with impaired cellular immune functions such
as renal transplant recipients and AIDS patients (Frazer, 1996).
Recently, a reduced expression of CD3-z and CD16-z on periph-
eral blood lymphocytes (PBL) from women with premalignant and
malignant cervical lesions was reported (Kono et al, 1996a). This
altered z chain expression was related to a reduced production of
tumour necrosis factor (TNF) upon polyclonal activation of
peripheral T-cells.
As z chain loss might represent a critical factor contributing to
an impaired HPV-specific T-cell-mediated immune response, we
decided to investigate the in situ z chain expression in primary and
metastatic cervical carcinoma-infiltrating lymphocytes using
immunohistochemical methods.
MATERIALS AND METHODS
Patients and specimens
Archives of the Pathology Departments of the Netherlands Cancer
Institute, the Free University Hospital and the Academic Medical
Center, Amsterdam, The Netherlands, were searched for primary
squamous cell cervical carcinoma specimens stored after 1994.
Whenever possible, frozen and fixed material from primary
tumours and the corresponding tumour-positive or -negative pelvic
lymph nodes were retrieved. Twenty-five different cases were iden-
tified. Paraffin-embedded tissue samples (n = 16) and frozen biop-
sies (n = 13) from in total 24 primary tumours were collected. For
five primary tumours both frozen and paraffin material was avail-
able. Paraffin blocks of tumour-negative (n = 15) and of tumour-
positive lymph nodes (n = 7) were retrieved. After histologic and
clinical file review, all cases were classified as moderately (6/25) or
poorly differentiated (19/25) squamous cell cervical carcinoma and
staged Ib—IIa according to the International Federation of
Gynaecology and Obstetrics (FIGO) staging system. Median
patient age was 47.8 years (25—78). All patients had undergone
radical hysterectomy with pelvic lymph node dissection as primary
surgery. In addition, three biopsies from cervical intraepithelial
neoplasia (CIN) patients (CIN III) and three cervical biopsies
without epithelial abnormalities were collected. As positive
controls, five hyperplastic tonsils were tested.
Monoclonal and polyclonal antibodies
The anti-TCR z monoclonal antibody TIA-2 (Coulter Clone,
Almere, NL), recognizing a cytoplasmic epitope of the TCR-asso-
ciated z chain was used to identify z chain-positive cells (dilution
1:25). To stain the CD3 complex, the mouse monoclonal antibody
Leu4 (Becton Dickinson, San Jose, CA, USA, dilution 1:10), or
rabbit polyclonal antibody A542 (DAKO, Glostrup, Denmark,
dilution 1:2000), both recognizing the CD3-e chain, were used.
Immunohistochemistry
Four 4-mm thick tissue sections were consecutively cut from each
specimen. Paraffin sections were mounted on 3% aminopropyl-
triethoxysilane-coated (Sigma, Deisenhofen, Germany) slides,
deparaffinized and rehydrated. After endogenous peroxidase
quenching (0.3% hydrogen peroxide methanol for 30 min), anti-
gens were ￿retrieved￿ either by boiling sections in sodium citrate
buffered solution (0.1 mM, pH 6.0) in a 750 kW microwave oven
at maximum power for 10 min (TIA-2) or by preincubating them
with 0.1% pronase E (Sigma, Deisenhofen, Germany) for 30 min
at 37°C (CD3-e). No antigen retrieval was used for TIA-2 or CD3-
e staining on frozen sections. Primary antibodies and isotype-
matched negative control antibodies at the appropriate dilutions
were incubated at room temperature (RT) for 1 h, except for the
rabbit polyclonal antibody A542 (O/N, 37°C). A biotinylated
secondary antibody to mouse or rabbit immunoglobulins (1:25,
30 min, RT, Dakopatts, Glostrup, Denmark) was followed by a
mouse monoclonal antibody directed against biotin (1:200,
30 min, RT, Southern Biotechnology Associates, IN, USA).
Complexed streptavidin-biotinylated horseradish peroxidase or
alkaline phosphatase was added (1:200 for 1 h, Dakopatts,
Glostrup, Denmark) and staining was visualized with diamino-
benzidine or new fuchsine on paraffin and frozen sections, respec-
tively. In each experiment, hyperplastic tonsils were included as
positive controls.
Scoring of CD3-e+ and CD3-z+ cells
Slides were examined and quantitatively scored by two indepen-
dent observers: a total of 100 tumour-infiltrating CD3-e+ cells
were counted in randomly selected high power fields (400 ´) of
tumour areas and CD3-z+ cells were similarly scored in the same
areas on consecutive slides. In lymph nodes, all CD3-e+ cells were
counted present in five HPF of interfollicular spaces or subcap-
sular sinuses. In the case of tumour-positive lymph nodes, HPF
were selected in the proximity of metastasizing tumour nests. For
each specimen, the CD3-z/e ratio was calculated and samples were
scored as follows: —, z/e = 0; +, 0 < z/e < 0.33; ++, 0.33 < z/e
< 0.66; +++, 0.66 < z/e < 1.0. z Chain expression was considered
to be down-regulated when the number of CD3-z+ cells was less
than 33% of the number of CD3-e+ cells (CD3-z/e <0.33, — or +).
When there was disagreement between the two observers, slides
were reviewed together until agreement was reached.
Statistical analysis
Frequencies of CD3-z down-regulation were compared between
test groups using the Fisher￿s exact test. Differences were regarded
as significant when P < 0.05.
RESULTS
CD3-z expression in primary cervical carcinomas
CD3+ cells, as determined by staining of the e chain of the CD3
complex, infiltrating the tumour fields were detectable in all 24
primary tumours studied. The z chain expression in the infiltrate
was considerably reduced compared to CD3-e expression (defined
by a CD3-z/e ratio of less than 0.33) in 17/24 (71%) of the primary
cervical carcinomas. Results obtained for all the studied tumours
are summarized in Table 1. Although we only quantified the
number of CD3-z+ cells within tumour fields, we also observed a
reduced z chain expression (as compared to CD3-e) in the stroma
surrounding the tumour areas (data not shown). However, this
reduction generally appeared to be less severe than the reduction
observed in infiltrating cells within the tumour mass. Figures 1C
and D show the respective CD3-e and CD3-z expression in
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reduction of z chain expression is apparent. The numeric differ-
ences between CD3-e+ and CD3-z+ cells was not due to immuno-
histochemical artifacts, since in slides with severely reduced z
chain expression it was always possible to find at least a few CD3-
z+ cells serving as internal positive controls. Although the neces-
sary microwave retrieval step on paraffin sections resulted in
considerably weaker staining for CD3-z than for CD3-e (Figure 1),
this did not lead to a bias in the quantitation, as evidenced by
results from frozen tissue sections: CD3-z staining on frozen
sections did not require antigen retrieval and was comparable in
intensity to the CD3-e staining, while similarly reduced CD3-z/e
ratios were found for paraffin and frozen sections from the same
tumours (n = 5, Table 1). CD3-e and CD3-z positive lymphocytes
(Figures 1A and B, respectively) are present in equal numbers in a
hyperplastic tonsil biopsy. A mean CD3-z/e ratio of 0.9 was found
for the total of five hyperplastic tonsils that were tested with only
minor variations between the different tonsil biopsies. These
tonsils served as positive controls in all performed tests. We also
determined CD3-z expression in three premalignant cervical
intraepithelial neoplastic (CIN) lesions (CIN III), which are
regarded as the direct precursor lesions of cervical carcinoma, and
in three cervical biopsies without apparent epithelial abnormali-
ties. We observed considerably reduced CD3-z expression in infil-
trating lymphocytes in two out of three CIN III lesions (CD3-z/e
<0.33) with the remaining CIN III lesion showing a less
pronounced reduction of CD3-z expression (0.33 < CD3-z/e
<0.67). The biopsies with normal cervical epithelium were harder
to analyse due to the absence of lymphocytes infiltrating the
squamous epithelial layers. However, no difference in the amount
of CD3-e+ and CD3-z+ cells was detected in T-cells present in the
stroma directly underneath the epithelial basal layer.
CD3-z expression in tumour-positive and
tumour-negative pelvic lymph nodes
A total of 15 tumour-negative and seven tumour-positive pelvic
lymph nodes were examined for CD3-e and z expression. In 11 out
of 15 tumour-negative lymph nodes CD3-e and CD3-z were
equally expressed, while only in one biopsy a considerably
reduced CD3-z expression was observed (CD3-z/e < 0.33). In
tumour-positive lymph nodes, tumour nests were usually
surrounded by a thick band of CD3-e+ cells, with some T-cells
intermingled with the tumour cells. In all seven tumour-positive
lymph nodes studied, CD3-z expression was strong and com-
parable to CD3-e expression (+++ in 6/7 and ++ in 1/7 cases, see
Table 1). Also on lymphocytes in between metastasizing tumour
cells a good CD3-z expression was observed. CD3-e and CD3-z
expression in a tumour-positive lymph node are shown in Figure
1E and F, respectively.
CD3-z expression in tumour-positive and tumour-negative
lymph nodes derived from the same patient was mostly com-
parable, except for case no. 7 where a reduced CD3-z expression
(comparable to the expression in the primary tumour) was observed
in the tumour-negative lymph node, while CD3-e and CD3-z were
equally expressed in the tumour-positive lymph node (Table 1).
From 14 patients both the primary tumour and tumour-negative
lymph nodes were available. In addition, tumour-positive lymph
nodes were also available from six of these patients (see Table 1).
The frequency of CD3-z loss (CD3-z/e < 0.33) in the primary
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Table 1 CD3-z expression in primary cervical tumours and draining pelvic lymph nodesa
Case no. Paraffin embedded Frozen Tumour-negative Tumour-positive
primary tumour primary tumour lymph nodeb lymph nodeb
1 + + +++ ND
2 + ND ++ ND
3+ ++ +N D
4 + + +++ +++
5+ + + ++ + N D
6 + ND +++ ++
7 + ND + +++
8 + ND +++ +++
9 ND ND +++ +++
10 + ND +++ +++
11 ++ ND +++ +++
12 + + ND ND
13 + ND +++ ND
14 + ND +++ ND
15 + ND +++ ND
16 ++ ND +++ ND
17 ++ ND ND ND
18 ND + ND ND
19 ND + ND ND
20 ND ++ ND ND
21 ND + ND ND
22 ND ++ ND ND
23 ND + ND ND
24 ND ++ ND ND
25 ND + ND ND
aCD3-z expression is classified according to the ratio of the number of CD3-z + cells and the number of CD3-e + cells in
the same areas in consecutive tissue sections; –, CD3-z/e = 0; +, 0 < CD3-z/e < 0.33; ++, 0.33 < CD3-z/e < 0.66; +++,
0.66 < CD3-z/e < 1.0, ND = not done. bLymph node biopsies were paraffin-embedded.tumours was significantly higher (11/14, 79%) than in the corre-
sponding tumour-negative lymph nodes (1/14, 7%, P < 0.0005).
Similarly, the frequency of CD3-z loss was higher in the primary
tumours (5/6, 83%) as compared to the corresponding metastasis-
positive draining lymph nodes (0/6, 0%, P < 0.02). Also, the
frequency of CD3-z down-regulation in the total of the tested
primary carcinomas (17/24, 71%) was significantly higher than
the frequency of down-regulation in all the lymph nodes (both
tumour-positive and tumour-negative) studied (1/22, 4.5%,
P < 0.00001, Figure 2).
DISCUSSION
In this study we report a putative local impairment of cellular
immune functions in primary cervical carcinoma due to the loss of
the signal transducing z chain from the TCR/CD3 complex of
tumour-infiltrating lymphocytes. In the majority of our carcinoma
samples, a down-regulation of CD3-z expression was observed as
compared to the expression of CD3-e in the same tumour fields on
consecutive slides. In contrast, CD3-z expression was retained in
T-cells surrounding metastatic deposits in draining pelvic lymph
nodes and also in tumour-negative lymph nodes.
The difference in expression levels between tumours and
draining lymph nodes suggests that the observed loss of CD3-z
expression is caused by factors released from the primary tumour
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A
B
C
D
E
F
Figure 1 CD3-e and CD3-z expression in a hyperplastic tonsil (A and B, respectively), a primary cervical tumour (C and D), and in a corresponding
metastasis-positive lymph node (E and F). CD3-e staining (A, C and E) was performed with the polyclonal antibody CD3 A542 and CD3-z (B, D, and F) with the
monoclonal antibody TIA-2. Size bars represent 100 mm
–
+
++
+++
CD3-z expression
Primary tumours Pelvic LN
Figure 2 CD3-z expression levels in primary cervical carcinomas (prim.
tumours, n = 24) and in both tumour-negative (n = 15) and in tumour-positive
(n = 7) draining pelvic lymph nodes (pelvic LN, total: n = 22). CD3-z
expression is classified according to the ratio of the number of z+ cells and
the number of CD3-Î+ cells in the same areas in consecutive tissue
sections; -: CD3-z/Î = 0, +: 0 < CD3-z/Î < 0.33, + +: 0.33 < CD3-z/Î < 0.66,
+ + +: 0.66 < CD3-z/Î < 1.0. CD3-z expression was considered to be lost in
case of – or + classification (CD3-z/Î < 0.33)and may be a localized effect. This is in keeping with previous
observations in colon carcinoma where CD3-z loss on mucosa-
infiltrating T-cells was found to be inversely correlated to the
distance from the primary tumour site (Matsuda et al, 1995).
However, employing FACS analysis, a down-regulation of CD3-z
has also been reported on peripheral lymphocytes from cervical
carcinoma patients (Kono et al, 1996a), indicating that this is not
merely a local effect. The latter study did not include an analysis of
tumour-infiltrating lymphocytes, but our study indicates that these
cells would have been likely to have had a more pronounced loss
of CD3-z expression. NK-cells can also express z chains which
associate with the low-affinity (type III) Fcg receptor (CD16)
(Kiessling et al, 1996). Indeed, besides loss of CD3-z from T-cells,
Kono et al (1996a) also showed down-regulation of z chains on
NK-cells in the peripheral blood of cervical carcinoma patients.
By staining carcinoma sections for the NK-cell marker CD56, we
found relatively few NK-cells infiltrating the tumour areas (data
not shown). We therefore conclude that the observed change in z
chain expression in cervical tumours is mainly due to the modula-
tion of CD3-z expression on tumour-infiltrating T-cells.
Our observation of putatively impaired T-cell functions in
cervical neoplasia by z chain down-regulation may seem to
conflict with our recently published findings of an increase in
granzyme B expression by CD8+ T-cells in cervical carcinoma,
which is a clear sign of cytotoxic T-cell (CTL) activation (Bontkes
et al, 1997). However, in early stage colon carcinomas (Duke￿s A)
we previously reported a similar increase in granzyme positivity
with a simultaneously decreased z chain expression (Mulder et al,
1997). It seems likely that, in tumours, the degree of T-cell activa-
tion on the one hand and T-cell suppression on the other, will
depend on the local balance between the availability of tumour
antigens accompanied by appropriate pro-inflammatory signals
and tumour-derived immunosuppressive factors (Matzinger, 1994;
Chouaib et al, 1997). To further study the direct relationship
between z chain expression and the ability of T-cells to express
granzyme B, a double-staining method for these markers will have
to be developed.
The mechanisms that are responsible for z chain loss in tumour-
infiltrating T-cells remain largely unclear. Experiments in tumour-
bearing mice have shown that the levels of z chain mRNA were not
affected but that proteolysis of the z chain was increased. Lysosomal
degradation was implicated as the cause of this increased rate of z
chain turnover (Correa et al, 1997). Immunosuppressive cytokines
such as IL-10 and TGF-b, possibly tumour-derived, might seem
obvious causative agents, but were shown to have no effect on CD3-
z expression in vitro (Kiessling et al, 1996). Recently, hydrogen
peroxide derived from tumour-associated macrophages was found
to down-modulate CD3-z expression on peripheral lymphocytes
(Kono et al, 1996b). Interestingly, macrophages isolated from lymph
nodes with melanoma metastases were shown to inhibit CD3-z
expression through contact-dependent mechanisms (Kiessling et al,
1996). Whether macrophage-derived factors are the main causative
agents responsible for the in vivo loss of CD3-z expression remains
to be established.
There are several possible explanations for the difference in
CD3-z expression we observed between primary cervical carci-
nomas and metastasis-positive lymph nodes: a differential expres-
sion of tumour- or macrophage-derived factors with z chain
modulating capacities in primary tumours and metastases, higher
levels of IL-2 in lymph nodes which may restore CD3-z expres-
sion (Kiessling et al, 1996), or a higher turnover rate of T-cells in
lymph nodes as compared to T-cells infiltrating the primary
tumour. A murine study demonstrated that T-cells must be exposed
for at least 26 days to the putative tumour-released factor, in order
for the CD3-z chain to be down-regulated (Mizoguchi et al, 1992).
Thus, a rapid turnover of T-cells in the lymph nodes might protect
them from z chain loss.
Kono et al (1996a) reported that the loss of CD3-z expression
on peripheral lymphocytes was already apparent in patients with
premalignant cervical lesions. This is in keeping with our finding
of a reduced CD3-z expression on epithelium-infiltrating lympho-
cytes in two out of three tested CIN III lesions. It remains to be
established whether decreased CD3-z expression is directly corre-
lated to the progression of cervical neoplastic lesions or rather is a
consequence of HPV infections per se. It is conceivable that CD3-
z down-modulation is a reaction to chronic antigenic stimulation
resulting from persistent HPV infections. In that case, CD3-z loss
might affect HPV-specific T-cell tolerance as has been hypothe-
sized for other pathogen- or tumour-specific immune responses
(Levey and Srivastava, 1996). This notion is in keeping with the
observed loss of CD3-z in such a chronic inflammatory condition
as rheumatoid arthritis (Kiessling et al, 1996; Maurice et al, 1998).
Whether only a generalized or also a specific effect, in either case
the loss of CD3-z from the signal transduction machinery of T-
cells is likely to hamper effective cellular immune responses to
HPV-transformed keratinocytes in (pre)malignant cervical lesions.
In conclusion, reduced CD3-z expression on T-cells infiltrating
primary cervical carcinomas may result in an impaired cell-medi-
ated anti-tumour response. In order for vaccination strategies to be
successful, it may be essential to first identify and counteract
mechanisms leading to this loss of CD3-z.
ACKNOWLEDGEMENTS
F Peccatori has been a recipient of a fellowship from the European
Cancer Centre, Amsterdam. This work was supported by the
Prevention Fund (28-1502.2) and the University Stimulation Fund
(USF) of the Free University.
REFERENCES
Bontkes HJ, de Gruijl TD, Walboomers JMM, van den Muysenberg AJC, Gunther
AW, Scheper RJ, Meijer CJLM and Kummer JA (1997) Assessment of
cytotoxic T-lymphocyte phenotype using the specific markers granzyme B and
TIA-1 in cervical neoplastic lesions. Br J Cancer 76: 1353—1360
Chouaib S, Asselin-Paturel C, Mami-Chouaib F, Caignard A and Blay JY (1997)
The host-tumor immune conflict: from immunosuppression to resistance and
destruction. Immunol Today 18: 493—497
Correa MR, Ochoa AC, Ghosh P, Mizoguchi H, Harvey L and Longo DL (1997)
Sequential development of structural and functional alterations in T cells from
tumor-bearing mice. J Immunol 158: 5292—5296
Cromme FV, Meijer CJLM, Snijders PJF, Uyterlinde A, Kenemans P, Helmerhorst T,
Stern PL, Vandenbrule AJC and Walboomers JMM (1993) Analysis of MHC
class-I and class-II expression in relation to presence of HPV genotypes in
premalignant and malignant cervical lesions. Br J Cancer 67: 1372—1380
Cromme FV, Walboomers JMM, Stukart MJ, de Gruijl TD, Kummer JA, Leonhart
AM, Helmerhorst TJM and Meijer CJLM (1995) Lack of granzyme expression
in T lymphocytes indicates poor cytotoxic T lymphocyte activation in human
papillomavirus-associated cervical carcinomas. Int J Gynecol Cancer 5:
366—373
de Gruijl TD, Bontkes HJ, Stukart MJ, Walboomers JMM, Remmink AJ,
Verheijen RHM, Helmerhorst TJM, Meijer CJLM and Scheper RJ (1996a)
T cell proliferative responses against human papillomavirus type 16 E7
oncoprotein are most prominent in cervical intraepithelial neoplasia patients
with a persistent viral infection. J Gen Virol 77: 2183—2191
CD3-z expression in cervical neoplasia 1131
British Journal of Cancer (1999) 79(7/8), 1127–1132 © Cancer Research Campaign 1999de Gruijl TD, Bontkes HJ, Walboomers JMM, Stukart MJ, Robbesom AAJP,
von Blomberg-van der Flier BME, Herbrink P, Remmink AJ,
Verheijen RHM, Helmerhorst TJM, Meijer CJLM and Scheper RJ (1996b)
Analysis of IgG reactivity against human papillomavirus type-16 E7 in
patients with cervical intraepithelial neoplasia indicates an association with
clearance of viral infection: results of a prospective study. Int J Cancer 68:
731—738
Finke JH, Zea AH Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O￿Shea JJ,
Kudou S, Klein E, Bukowski RM and Ochoa A (1993) Loss of T-cell receptor
zeta chain and P56lck in T-cells infiltrating human renal cell carcinoma.
Cancer Res 53: 5613—5616
Frazer IH (1996) Immunology of papillomavirus infection. Curr Op Immunol 8:
484—491
IARC (1995) Monographs on the Evaluation of the Carcinogenic Risks to Humans,
vol. 64, The Human Papillomavirus. International Agency for Research on
Cancer: Lyon
Kiessling R, Kono K, Petersson M and Wasserman K (1996) Immunosuppression in
human tumor-host interaction: role of cytokines and alterations in signal-
transducing molecules. Springer Sem Immunopatol 18: 227—242
Kono K, Ressing ME, Brandt RMP, Melief CJM, Potkul RK, Andersson B,
Petersson M, Kast WM and Kiessling R (1996a) Decreased expression of
signal-transducing zeta chain in peripheral T cells and natural killer cells in
patients with cervical cancer. Clin Cancer Res 2: 1825—1828
Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K,
Nakazawa T, Andersson P and Kiessling R (1996b) Hydrogen peroxide
secreted by macrophages/monocytes inhibits tumor specific T-cell and NK
mediated cytotoxicity and down-regulates expression expression of signal-
transducing molecules. Eur J Immunol 26: 1308—1313
Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G and Whiteside
TL (1996) Alterations in expression and function of signal-transducing proteins
in tumour-associated T and natural killer cells in patients with ovarian
carcinoma. Clin Cancer Res 2: 161—173
Levey DL and Srivastava PK (1996) Alterations in T cells of cancer-bearers: whence
specificity? Immunol Today 17: 365—368
Matsuda M, Petersson M, Lenkei R, Taupin J-L, Magnusson I, Mellstedt H,
Andersson P and Kiessling R (1995) Alterations in the signal-transducing
molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal
and peripheral lymphocytes: correlation with the stage of the disease. Int J
Cancer 61: 765—772
Matzinger P (1994) Tolerance, danger and the extended family. Annu Rev Immunol
12: 991—1045
Maurice MM, Lankester AC, Bezemer AC, Geertsma MF, Tak PP, Breedveld FC,
van Lier RAW and Verweij CL (1998) Defective TCR-mediated signaling in
synovial T cells in rheumatoid arthritis. J Immunol 159: 2973—2978
Mizoguchi H, O￿Shea JJ, Longo DL, Loeffler CM, McVicar DW and Ochoa A
(1992) Alterations in signal transduction molecules in T-lymphocytes from
tumor bearing mice. Science 258: 1795—1798
Mulder WMC, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J and Scheper RJ
(1997) T cell receptor-zeta and granzyme B expression in mononuclear cell
infiltrates in normal colon mucosa and colon carcinoma. Gut 40: 113—119
Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H,
Taupin J-L, Vivier E, Anderson P and Kiessling R (1993) Decreased
expression of the signal-transducing zeta chains in tumor-infiltrating
T-cells and NK cells of patients with colorectal carcinoma. Cancer Res 53:
5610—5612
Robey E and Allison JP (1995) T-cell activation: integration of signals from the
antigen receptor and costimulatory molecules. Immunol Today 16: 306—310
Rosenberg AS (1996) Development of cancer immunotherapies based on
identification of the genes encoding cancer regression antigens. J Natl Cancer
Inst 88: 1635—1644
Tartour E, Latour S, Mathiot C, Thiounn N, Mosseri V, Joyeux I, D￿Enghien CD,
Lee R, Derbre B and Fridman WH (1995) Variable expression of CD3-zeta
chain in tumor-infiltrating lymphocytes (TIL) derived from renal-cell
carcinoma: relationship with TIL phenotype and function. Int J Cancer 63:
205—212
Whiteside TL, Jost LM and Herbermann RB (1992) Tumor-infiltrating lymphocytes.
Potential and limitations to their use for cancer therapy. Crit Rev Oncol
Hematol 12: 25—47
Zea AH, Curti BD, Longo CD, Alvord WG, Srobl SL, Mizoguchi H, Creekmore SP,
O￿Shea JJ, Powers GC, Urba WJ and Ochoa AC (1995) Alteration in T cell
receptor and signal transduction molecules in melanoma patients. Clin Cancer
Res 1: 1327—1335
1132 TD de Gruijl et al
British Journal of Cancer (1999) 79(7/8), 1127–1132 © Cancer Research Campaign 1999